Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Cardiac Amyloidosis: Everywhere, but Nowhere
Author(s): Aqtab Mazhar Alias , Raja Ezman Raja Shariff , Norashikin Saidon , et al Added: 1 year ago

Heart Failure
The Evolving Treatment Landscape for HFpEF in Cardiac Amyloidosis
Author(s): Added: 2 months ago
AHA Scientific Sessions 2025 - Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview… View more

Heart Failure
AHA 25: The AI-SCREEN-CA Study
Author(s): Nobuyuki Kagiyama Added: 2 months ago
AHA Scientific Sessions 2025 - Prof Nobuyuki Kagiyama (Juntendo University School of Medicine, Tokyo, JP) joins us to share findings from the AI-SCREEN-CA study investigating whether an artificial intelligence-based software for checking real-world echocardiography can improve the early and accurate detection of hidden cardiac amyloidosis.Findings showed that this AI software identified around 5%… View more

Heart Failure

Imaging & Diagnostics
High-sensitivity Troponin in Cardiac Surgery
Author(s): Cuilin Zhu , Xiaomeng Wang , Xiao Liu , et al Added: 3 weeks ago

MI/ACS
Digital Healthcare in Cardiac Prevention Programme in Indonesia
Author(s): Bambang Dwiputra , Ade Meidian Ambari , Dwita Rian Desandri , et al Added: 1 year ago

Digital Health

Prevention & Chronic Conditions
ACC 25: Cardiac Biomarker Analysis from the EARLY TAVR Trial
Author(s): Brian Lindman Added: 9 months ago
ACC 2025 - Primary findings from EARLY-TAVR show the benefit of early TAVR intervention was consistent across biomarker subgroups.Dr Brian Lindman (Vanderbilt University Medical Center, Nashville, US) joins us onsite at ACC 2025 to discuss findings from the primary biomarker analysis from the EARLY TAVR trial (NCT03042104; Edwards Lifesciences). The analysis investigated cardiac biomarkers in… View more

Vascular Disease and Surgery
Efficacy and Safety of LAAO during Cardiac Surgery to Prevent Stroke
Author(s): Reynald Evan R Tugade , Billy Joseph David , Clara S Tolentino Added: 1 year ago

Electrophysiology & Arrhythmia

Prevention & Chronic Conditions
AHA 24: Nexiguran Ziclumeran for ATTR-CM
Author(s): Marianna Fontana Added: 1 year ago
AHA Conference 2024 - Safety and efficacy outcomes of nexiguran ziclumeran (NTLA-2001) in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).Dr Marianna Fontana (University College London, London, UK) joins us onsite at AHA Conference to discuss the findings from the nexiguran ziclumeran for ATTR-CM trial (NCT04601051).Dr Fontana discusses a phase 1, ongoing, open-label, single… View more

Heart Failure
ESC 25 Hot Line Discussion: DIGIT-HF: Cardiac Glycosides in HFrEF
Author(s): Harriette Van Spall , Udo Bavendiek Added: 4 months ago
ESC Congress 2025 - Digitoxin reduced the risk of all-cause mortality and hospitalisation in patients with worsening heart failure.Dr Harriette Van Spall (McMaster University, CA) sits down with Prof Udo Bavendiek to explore the DIGIT-HF trial, investigating whether digitoxin can improve outcomes in patients with advanced chronic heart failure and reduced ejection fraction.This landmark study… View more

Heart Failure

Prevention & Chronic Conditions
Post-COVID-19 Myocarditis Identified using CMR
Author(s): Reynald Evan R Tugade , Nyssa Elline Palileo , Danica Ann Leycano , et al Added: 1 year ago

Imaging & Diagnostics